From the Journals

Smoking-attributable cancer mortality highest in Kentucky


 

Almost 29% of cancer deaths among U.S. adults aged 35 years and older were attributable to cigarette smoking in 2014, according to investigators from the American Cancer Society.

Of the 585,000 cancer deaths among those 35 years and older that year, more than 167,000 (28.6%) were estimated to be the result of cigarette smoking, reported Joannie Lortet-Tieulent, MSc, and her associates at the ACS in Atlanta (JAMA Intern Med. 2016 Oct 24. doi: 10.1001/jamainternmed.2016.6530).

Cancer deaths attributable to cigarette smoking in adults aged 35 and older, 2014
Kentucky had the highest proportion of cancer deaths attributable to cigarette smoking at 34.0%, followed by Arkansas (33.5%), Tennessee (32.9%), West Virginia (32.6%), and Louisiana (32.6%). Utah was in a class by itself at the low end of the scale with a smoking-attributable cancer mortality of 16.6%, with California next highest at 25.5%, they said.

Among men aged 35 years and older, 33.7% of U.S. cancer deaths were attributable to cigarette smoking, compared with 22.9% for women. Arkansas had the highest rate (39.5%) for men and Kentucky had the highest rate (29.0%) for women. Not surprisingly, Utah had the lowest rate for both men (21.8%) and women (11.1%), according to the analysis of data from the 2014 Behavioral Risk Factor Surveillance System. For men, Utah was the only state with a rate below 30%.

The investigators did not report any conflicts of interest. The study was supported by the intramural research department of the American Cancer Society.

Recommended Reading

Clinicians call for expanded pulmonary palliative care
MDedge Hematology and Oncology
Recommendations for Cancer Moonshot overlook a few issues, YSC says
MDedge Hematology and Oncology
Racial gaps persist in lung cancer trial enrollment
MDedge Hematology and Oncology
NSCLC survival comparable with accelerated and conventional RT
MDedge Hematology and Oncology
Glimmer of promise for nivolumab in neoadjuvant NSCLC therapy
MDedge Hematology and Oncology
Patients with stage 1 NSCLC more likely to die of other causes in short term
MDedge Hematology and Oncology
Pembrolizumab boosts response but not survival in small study of advanced NSCLC
MDedge Hematology and Oncology
OAK: Atezolizumab grows OS in advanced NSCLC
MDedge Hematology and Oncology
Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLC
MDedge Hematology and Oncology
FDA approves atezolizumab for advanced NSCLC
MDedge Hematology and Oncology